Browse ZNF433

Summary
SymbolZNF433
Namezinc finger protein 433
Aliases FLJ40981
Chromosomal Location19p13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF01352 KRAB box
Function

May be involved in transcriptional regulation.

> Gene Ontology
 
Biological Process -
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
Summary
SymbolZNF433
Namezinc finger protein 433
Aliases FLJ40981
Chromosomal Location19p13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ZNF433 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolZNF433
Namezinc finger protein 433
Aliases FLJ40981
Chromosomal Location19p13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ZNF433 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.56 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolZNF433
Namezinc finger protein 433
Aliases FLJ40981
Chromosomal Location19p13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ZNF433 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.060.818
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2260.649
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2660.539
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1050.801
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1350.957
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4080.897
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.7580.014
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.0490.129
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3690.588
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.330.73
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9250.458
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0340.754
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolZNF433
Namezinc finger protein 433
Aliases FLJ40981
Chromosomal Location19p13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ZNF433. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolZNF433
Namezinc finger protein 433
Aliases FLJ40981
Chromosomal Location19p13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ZNF433. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ZNF433.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolZNF433
Namezinc finger protein 433
Aliases FLJ40981
Chromosomal Location19p13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ZNF433. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolZNF433
Namezinc finger protein 433
Aliases FLJ40981
Chromosomal Location19p13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ZNF433 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolZNF433
Namezinc finger protein 433
Aliases FLJ40981
Chromosomal Location19p13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ZNF433 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolZNF433
Namezinc finger protein 433
Aliases FLJ40981
Chromosomal Location19p13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ZNF433 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.